Dyadic International (NASDAQ:DYAI) Stock Price Crosses Below Fifty Day Moving Average – Here’s What Happened

Dyadic International, Inc. (NASDAQ:DYAI) shares crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $1.64 and traded as low as $1.37. Dyadic International shares last traded at $1.50, with a volume of 114,192 shares.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Dyadic International in a research report on Thursday, November 14th.

Dyadic International Trading Down 1.3 %

The stock has a market capitalization of $43.79 million, a PE ratio of -6.43 and a beta of 0.89. The company has a current ratio of 5.15, a quick ratio of 5.15 and a debt-to-equity ratio of 1.54. The business’s 50-day moving average is $1.63 and its two-hundred day moving average is $1.41.

Institutional Investors Weigh In On Dyadic International

Several institutional investors and hedge funds have recently modified their holdings of DYAI. Inlet Private Wealth LLC purchased a new stake in shares of Dyadic International during the 4th quarter valued at about $52,000. Bank of America Corp DE grew its position in Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 26,965 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Dyadic International during the fourth quarter valued at approximately $28,000. Jane Street Group LLC acquired a new position in shares of Dyadic International during the fourth quarter worth $45,000. Finally, Two Sigma Securities LLC acquired a new position in shares of Dyadic International during the fourth quarter worth $25,000. Hedge funds and other institutional investors own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.